- Home
- SSSS vs XGN Comparison
SSSS vs XGN Comparison
Compare SSSS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSSS | XGN |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.3M | 253.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SSSS | XGN |
|---|---|---|
| Price | $9.10 | $6.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $10.13 | ★ $13.67 |
| AVG Volume (30 Days) | 161.5K | ★ 250.3K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 10.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | $2,354,933.00 | ★ $63,599,000.00 |
| Revenue This Year | $7,183.09 | $22.15 |
| Revenue Next Year | N/A | $15.26 |
| P/E Ratio | $3.51 | ★ N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $4.21 | $2.67 |
| 52 Week High | $10.34 | $12.23 |
Technical Indicators
Market Signals| Indicator | SSSS | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 23.28 |
| Support Level | $9.36 | $7.01 |
| Resistance Level | $9.60 | $7.29 |
| Average True Range (ATR) | 0.28 | 0.34 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 9.58 | 1.95 |
Price Performance
Historical ComparisonAbout SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.